Show simple item record

dc.contributor.authorLi, Ming
dc.contributor.authorKnight, Deborah A.
dc.contributor.authorJ. Smyth, Mark
dc.contributor.authorStewart, T.
dc.date.accessioned2017-05-03T16:13:11Z
dc.date.available2017-05-03T16:13:11Z
dc.date.issued2012
dc.date.modified2013-09-01T23:21:10Z
dc.identifier.issn03407004
dc.identifier.doi10.1007/s00262-012-1200-1
dc.identifier.urihttp://hdl.handle.net/10072/47248
dc.description.abstractCancer stem cells (CSC) are resistant to radiation and chemotherapy and play a significant role in cancer recurrence and metastatic disease. It is therefore important to identify alternative strategies, such as immunotherapies that can be used to control this refractory population. A CD44?CD24-/low subpopulation of cells within the B6 PyMT-MMTV transgenic mouse-derived AT-3 mammary carcinoma cell line was identified, which had CSC-like characteristics, including pluripotency and a resistance to chemo- and radiotherapy. Therefore, unlike xenograph models that require immunocompromised settings, this novel system may provide a means to study immune-mediated responses against CSC-like cells. The immunobiology of the AT-3 CSC-like cell population was studied by their surface molecule expression profile and their sensitivity to specified cell death pathways. Comparable levels of Rae-1, CD155, CD54 and higher levels of Fas and DR5 were expressed on the AT-3 CSC-like cells compared to non-CSC-like tumor cells. Expression correlated with an in vitro sensitivity to cell death by NK cells or through the ligation of the death receptors (Fas or DR5), by their ligands or anti-Fas and anti-DR5 mAbs. Indeed, compared to the rest of the AT-3 tumor cells, the CD44?CD24-/low subpopulation of cells were more sensitive to both Fas- and TRAIL-mediated cell death pathways. Therefore, despite the refractory nature of CSC to other conventional therapies, these CSC-like cells were not inherently resistant to specified forms of immune-mediated cell death. These results encourage the continued investigation into immunotherapeutic strategies as a means of controlling breast CSC, particularly through their cell death pathways.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.format.extent617234 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.publisher.placeGermany
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom1255
dc.relation.ispartofpageto1268
dc.relation.ispartofissue8
dc.relation.ispartofjournalCancer Immunology, Immunotherapy
dc.relation.ispartofvolume61
dc.rights.retentionY
dc.subject.fieldofresearchCancer Cell Biology
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchcode111201
dc.subject.fieldofresearchcode1107
dc.titleSensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.rights.copyright© 2012 Springer Berlin / Heidelberg. This is an electronic version of an article published in Cancer Immunology, Immunotherapy, August 2012, Volume 61, Issue 8, pp 1255-1268. Cancer Immunology, Immunotherapy is available online at: http://link.springer.com// with the open URL of your article.
gro.date.issued2012
gro.hasfulltextFull Text
gro.griffith.authorStewart, Trina


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record